The Netherlands Enterprise Agency granted an Innovation Credit (’Innovatiekrediet’) of € 3.4 million to Dutch biopharma SME Alloksys Life Sciences for the execution of phase 3 clinical trials. The goal is to reach registration of RESCAP® (RESCuing Alkaline Phosphatase).

Founded in 2006, Alloksys Life Sciences is developing the platform as an anti-ischemic injury and anti-inflammatory compound in acute clinical settings like open heart and other major surgery, organ transplantation, blood loss trauma and severe burn wounds.